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Background: Our aim was to identify the pancreatic cancer diabetogenic peptide.
Methods: Pancreatic tumor samples from patients with (n=15) or without (n=7) diabetes were compared with 6 non-neoplastic pancreas samples
using SDS-PAGE.
Results: A band measuring approximately 1500 Da was detected in tumors from diabetics, but not in neoplastic samples from non-diabetics or
samples from non-neoplastic subjects. Sequence analysis revealed a 14 amino acid peptide (1589.88 Da), corresponding to the N-terminal of the
S100A8. At 50 nmol/L and 2 mmol/L, this peptide significantly reduced glucose consumption and lactate production by cultured C2C12
myoblasts. The 14 amino acid peptide caused a lack of myotubular differentiation, the presence of polynucleated cells and caspase-3 activation.
Conclusions: The 14 amino acid peptide from S100A8 impairs the catabolism of glucose by myoblasts in vitro and may cause hyperglycemia in
vivo. Its identification in biological fluids might be helpful in diagnosing pancreatic cancer in patients with recent onset diabetes mellitus.
© 2006 Elsevier B.V. All rights reserved.Keywords: Pancreatic cancer; Diabetes mellitus; S100A8; Chronic pancreatitis; Myoblasts; Apoptosis1. Introduction
While some epidemiological studies indicate that diabetes
mellitus, which occurs in about 80% of patients with pancreatic
adenocarcinoma [1,2], is a risk factor for this tumor type, others
suggest that pancreatic adenocarcinoma causes diabetes mellitus
[3,4]. Although diabetes mellitus, especially when insulin
treated, may predispose patients to pancreatic cancer, findings
in epidemiologic, clinical and experimental studies have
demonstrated that this metabolic alteration is caused by
pancreatic cancer [5–10]: following tumor excision, glucose
tolerance often ameliorates, sometimes returning to normal [2,5].
Moreover, mice treated with pancreatic cancer cell conditioned
media develop hyperglycemia [6].⁎ Corresponding author. Tel.: +39 0498212792; fax: +39 049663240.
E-mail address: mario.plebani@unipd.it (M. Plebani).
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doi:10.1016/j.cca.2006.03.027The pathophysiological mechanism underlying pancreatic
cancer-associated diabetes probably depends on alterations in
beta cell function and glucosemetabolism occurring in peripheral
tissues. Ding et al. [9] have demonstrated that pancreatic cancer
cell conditioned media can dissociate insulin from amylin
secretion in beta-cells. Elsewhere, we demonstrated that the C-
peptide response to physiological stimuli (e.g., meal or i.v.
glucagon) is reduced in pancreatic cancer patients [11].
Furthermore, glycolysis is impaired in hepathocytes cultured in
pancreatic cancer cell conditionedmedia, probably because these
media reduce glycolysis, causing a metabolic shift at the triose
level sustained by the accumulation of the tryglycerides synthesis
intermediate 1,2-diacylglycerol [10].
Pancreatic cancer also causes glucose metabolic alterations in
skeletal muscle cells: due to glycogen phosphorylase activation
and glycogen synthase inhibition, a skeletal muscle glycogen
breakdown prevails over glycogen synthesis, the transcription
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Fig. 1. SDS-PAGE, obtained in cancer tissue samples of patients with or without
diabetes mellitus (A), in pancreatic cancer and adjacent disease-free tissue
samples from one patientwith cancer-associated diabetes (B), in pancreatic cancer
cell line lysates or a pancreatic tissue sample from a patient with chronic
pancreatitis (C). (A) M=molecular weight marker; 1 and 3= tumor tissues from
patients with diabetes mellitus; 2 and 4=tumor tissues from patients without
diabetes mellitus. (B)M=molecular weightmarker; 1=disease-free tissue sample
adjacent to the tumor; 2=tumor. (C) M=molecular weight marker; 1=BxPC3;
2=CAPAN-1; 3=MIAPaCa 2; 4=pancreatic tissue sample from one patient with
chronic pancreatitis. Arrows indicate the peptide band of 1500 Da, detected in
cancer tissues from patients with diabetes and in cancer cell line lysates.
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demonstrated in vitro that pancreatic cancer cell conditioned
media do not alter myoblastic transcription levels of several
glycolytic enzymes; nor do they alter the levels of enzymes
involved in glycogen synthesis or degradation, although they
markedly affect glucose metabolism [13]. The glucose consump-
tion by pancreatic cancer conditioned myoblasts is enhanced, as
is lactate production. This effect, also achieved by incubating
myoblasts with pancreatic tumor homogenates, is magnified in
homogenates from patients with pancreatic cancer-associated
diabetes mellitus.
Furthermore, in the skeletal muscle of pancreatic cancer
patients, and in pancreatic cancer conditioned myoblasts,
proteolysis overcomes protein synthesis, and this probably
contributes to cancer cachexia [13,14], suggested to be caused
by the proteolysis inducing factor (PIF) peptide, isolated form
pancreatic tumors [14,15]. Pancreatic cancer-associated diabetes,
in turn, is believed to be caused by an as-yet unidentified low-
molecular-weight peptide [9,10,16].
The aim of the present study was therefore to identify and
characterize the pancreatic cancer associated diabetogenic factor.
2. Materials and methods
We studied 22 patients (9 males, 13 females; age range 41–
83 years) with and 6 patients (4 males, 2 females; age range 28–
65 years) without pancreatic cancer, who had chronic pancreatitis
(2 cases), benign stenosis of the Wirsung duct (1), duodenal
leiomyosarcoma (1), duodenal adenocarcinoma (1) and pancreas
divisum (1). Pancreatic tumor stage was stage II (3 cases), stage
III (13 cases) and stage IV (6 cases). Diabetes mellitus, diagnosed
following the American Diabetes Association criteria [17], was
found in 15 patients with pancreatic cancer and in 1 with chronic
pancreatitis. Two of the 15 pancreatic cancer patients with
diabetes mellitus were insulin treated and three received oral anti-
diabetics. Insulin plasma levels were significantly reduced
(b2.0 mU/L) in seven (including the 2 insulin-treated pts) and
significantly enhanced (N24 mU/L) in one pancreatic cancer
patient, but were within the reference range in all the other
subjects. All patients underwent abdominal surgery, with
intraoperative pancreatic sampling: from pancreatic cancer
patients, two tissue samples were obtained, one from the tumor
mass and the other from the adjacent disease-free pancreatic
tissue; from patients without pancreatic cancer, one pancreatic
sample was obtained. All samples were immediately frozen in
liquid nitrogen and stored at −80 °C until laboratory analysis.
Neoplastic and non-neoplastic tissue samples were homoge-
nized (1:5 w/v) in ice-cold phosphate-buffered saline (PBS) pH
7.4. In tissue homogenates, the total protein content was
measured using Bradford's method (Bio-Rad Laboratories S.r.
l., Milano, Italy) [18]. Proteins (100 μg) were denatured in
Laemmli's buffer [60 mM Tris–HCl (pH 6.8), 20% glycerol,
10% β-mercaptoethanol, 4.6% SDS, and 0.003% bromophenol
blue], and separated using the 16.5% discontinuous sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) system [19]. Electrophoresis was performed at 10 °C
(Cryostats Bath, MPM Instruments Srl, Bernareggio, Milano,Italy) for 16 h at 80 V. The protein bands were fixed for 1 h in a
solution containing 50% methanol and 10% acetic acid, before
being stainedwith 0.025%Brilliant blueG (SigmaChemical Co.,
USA) in 10% acetic acid. De-stainingwas achieved in 10% acetic
acid. The SDS-PAGE separated proteins of a pancreatic tumor
sample from a diabetic patient were electro-blotted on a
polyvinilydene difluoride (PVDF) membrane (Hybond P,
Amersham, Les Ulis, France) using a Trans-Blot Electrophoretic
Transfer Cell (Bio-Rad Laboratories S.r.l., Milano, Italy). After
Coomassie staining of the PVDF membrane, the peptide band to
be investigated was cut and loaded into the sample cell of a
Procise mod 491 Protein sequencer (Applied Biosystems,
Farmington, MA, USA). Automated Edman degradation was
carried out for 20 cycles following the manufacturer's instruc-
tions. The peptide was then synthesized by Primm s.r.l. (Milano,
Italy) at a purity grade of more than 95% (reversed-phase high-
performance liquid chromatography).
Three pancreatic cancer cell lines (BxPC3, CAPAN-1 and
MIA PaCa 2) and the myogenic mice cell line C2C12 were used.
Cells were cultured in DMEM with added 0.1% gentamycin and
10% fetal calf serum (FCS) (BxPC3, MIA PaCa 2 and C2C12) or
RPMI with added 0.1% gentamycin and 20% FCS (CAPAN-1).
Harvested cells (500,000), diluted in 50 μL phosphate-buffered
saline pH 7.4, were lysed and loaded onto SDS-PAGE gels. For
the experiments with synthesized peptide, 60,000 C2C12 cells
were seeded in each well of a 24-well culture plate and incubated
with low glucose (5.4 mmol/L) DMEM, plus 10% FCS for 24 h.
Table 1
Glucose levels (mean±S.D.) measured in control myoblasts and myoblasts incubated with increasing peptide concentrations
Hours of incubation MANOVA
0 24 48 72 Within subjects Between subjects
Control (n=13) 25±2.4 mM 23±1.2 mM 17±0.6 mM 13±1.1 mM F=5.23, pb0.05 F=0.174, p: ns
2 mM Peptide (n=4) 23±3.8 mM 21±2.2 mM 18±0.4 mM 16±0.8 mM
Control (n=15) 24±3 mM 21±3.2 mM 16±3.6 mM 11±3.9 mM F=2.4, p: ns F=1.7, p: ns
1 mM Peptide (n=7) 21±3.6 mM 18±4.8 mM 14±6.3 mM 11±6.9 mM
Control (n=20) 23±3.4 mM 21±3.1 mM 15±3.2 mM 10±3.4 mM F=0.13, p: ns F=2.86, p: ns
500 μM Peptide (n=8) 21±3.2 mM 18±3.6 mM 13±4.4 mM 8±3.9 mM
Control (n=8) 20±0.7 mM 19±0.8 mM 15±1.2 mM 10±1.2 mM F=0.1, p: ns F=0.18, p: ns
300 μM Peptide (n=5) 20±0.9 mM 18±0.5 mM 15±1.4 mM 9±1.6 mM
Control (n=7) 20±1.2 mM 19±1.2 mM 16±1.6 mM 10±1.1 mM F=1.76, p: ns F=0.41, p: ns
150 μM Peptide (n=4) 20±1.8 mM 18±1.5 mM 16±0.7 mM 11±2.3 mM
Control (n=13) 21±0.8 mM 19±0.9 mM 16±1.8 mM 11±2.2 mM F=0.98, p: ns F=1.19, p: ns
75 μM Peptide (n=8) 20±0.4 mM 19±0.8 mM 16±1.6 mM 9±2.9 mM
Control (n=12) 20±0.6 mM 19±0.9 mM 16±1.7 mM 11±3.1 mM F=0.62, p: ns F=0.69, p: ns
35 μM Peptide (n=9) 20±0.4 mM 19±1.0 mM 17±1.8 mM 12±4.5 mM
Control (n=8) 20±0.7 mM 19±1.2 mM 17±1.7 mM 12±3.4 mM F=0.07, p: ns F=0.33, p: ns
15 μM Peptide (n=5) 20±0.4 mM 19±0.7 mM 17±1.6 mM 13±4.7 mM
Control (n=13) 21±0.8 mM 17±2.3 mM 13±3.9 mM F=0.105, p: ns F=0, p: ns
7.5 μM Peptide (n=15) 20±0.9 mM 17±2.3 mM 14±4.1 mM
Control (n=12) 21±0.3 mM 19±0.9 mM 16±2.7 mM 13±3.9 mM F=0.06, p: ns F=0.1, p: ns
1 μM Peptide (n=13) 20±0.3 mM 19±1.1 mM 16±3.3 mM 12±2.3 mM
Control (n=3) 21±0.6 mM 18±0.4 mM 11±0.4 mM 6±0.5 mM F=0.3, p: ns F=0.38, p: ns
500 nM Peptide (n=4) 21±0.8 mM 17±0.8 mM 11±0.3 mM 6±0.6 mM
Control (n=16) 20±0.8 mM 18±1.8 mM 14±4.2 mM 10±5.2 mM F=0.17, p: ns F=0.05, p: ns
100 nM Peptide (n=19) 20±0.9 mM 18±2.1 mM 15±4.5 mM 11±5.9 mM
Control (n=5) 20±1.4 mM 16±1.8 mM 9±1.9 mM 4±2.2 mM F=3.45, pb0.05 F=1.17, p: ns
50 nM Peptide (n=5) 20±1.5 mM 18±2.8 mM 13±5.1 mM 8±5.5 mM
Control (n=13) 21±0.4 mM 19±1.1 mM 16±3.1 mM 12±4.1 mM F=0.16, p: ns F=0.44, p: ns
10 nM Peptide (n=14) 21±0.4 mM 19±1.1 mM 17±2.6 mM 13±3.9 mM
Control (n=3) 20±0.3 mM 19±0.8 mM 16±2.5 mM 14±3.9 mM F=0.03, p: ns F=0.04, p: ns
1 nM Peptide (n=5) 20±0.4 mM 19±0.9 mM 16±2.4 mM 14±4.1 mM
For each concentration, the corresponding control values, obtained in the same experimental runs, are reported. Each experiment was repeated at least three times and
the number of data used in each statistical analysis is reported in brackets. No data were available at 24 h of incubation for the 75 μM peptide. The statistical analysis
was made using MANOVA.
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(20 mmol/L) DMEM, plus 10% FCS, and the pure peptide in
increasing concentrations (from nmol/L to 2 mmol/L). Media
were collected after 24, 48 and 72 h incubation. All experiments
weremade in triplicate, a set of at least three separate experiments
being performed. Control myoblasts were run throughout each
experiment. Glucose and lactate were measured within 3 h of
collection using a colorimetric method on an automatic analyzer
(Dimension RxL, Dade Behring, Milan, Italy).
For cell growth experiments, 600 C2C12 cells/well were
seeded in duplicate in a 96-well culture plate and incubated with
control medium (DMEM) and different amounts of peptide.
Viable cells were estimated after 24, 48 and 72 h using the XTT
cell proliferation assay (Roche Diagnostics GmbH, Germany).
At least three different sets of experiments were performed.
For apoptosis experiments, 1×106 C2C12 myoblasts were
plated in Petri dishes (80 cm2 growth area) and incubated in
DMEM (negative control cells), in DMEM added with
0.01 mmol/L of the apoptosis inducer, 5-fluorouracil (5-FU-
positive control cells) or 50 nmol/L peptide (tested cells). After
28 h incubation, cells were scraped, washed once with PBS and
re-suspended at a concentration of 2×106/100 μL in the ice-cold
Cell Lysis Buffer provided with the assay kit for caspase-3
activity determination (Calbiochem, Germany). Caspase-3activity was measured in cell lysates following the manufac-
turer's instructions. Seven different negative control cells plates,
five different tested cells plates and three different positive
control cells plates were used to determine caspase-3 activity.
Electrospray ionization (ESI)-mass spectra were acquired
using a ion trap LCQ Deca instrument (Thermo Electron, USA).
Negative ion ESI-mass spectra of a 10−5 mol/L solution (50:50
water/acetonitrile) were obtained by direct infusion using a
syringe pump at 8 μL/min. The operative conditions were
capillary temperature=230 °C; capillary voltage=−15 V; source
voltage=−5 kV.
Peripheral blood mononuclear cells were isolated from the
blood of healthy donors by Ficoll-Hypaque gradient centrifuga-
tion (Histopaque, Sigma-Aldrich Inc., USA). Monocytes,
purified using the MACS CD14 isolation kit (Mylteni Biotec,
Bergisch Gladbach, Germany), were cultured in six-well plates
(1–2×106 cells/mL) in fresh complete medium (RPMIwith 10%
FCS and 1% glutamine) overnight. Media were then replaced
with the following: (1) fresh complete medium (control
monocytes); (2) 4 days CAPAN-1 conditioned medium (condi-
tioned monocytes); (3) fresh complete medium with 1 and 5 μg/
mL lipopolysaccharide (LPS stimulated control monocytes); (4)
4 days CAPAN-1 conditioned medium with 1 and 5 μg/mL LPS
(LPS stimulated conditioned monocytes). Media were collected
Table 2
Lactate levels (mean±S.D.) measured in control myoblasts and in myoblasts incubated with increasing peptide concentrations
Hours of incubation MANOVA
0 24 48 72 Within subjects Between subjects
Control (n=13) 3±0.2 mM 7±1.5 mM 16±4.2 mM 26±5.5 mM F=5.72, pb0.05 F=4.9, pb0.05
2 mM Peptide (n=4) 3±0.1 mM 6±2.5 mM 11±6.4 mM 17±8.4 mM
Control (n=15) 3±0.2 mM 8±1.8 mM 18±5.2 mM 27±6.4 mM F=4.38, pb0.05 F=3.14, p: ns
1 mM Peptide (n=7) 3±0.1 mM 6±3.1 mM 14±8.3 mM 19±10.8 mM
Control (n=20) 3±0.2 mM 7±1.7 mM 17±5.5 mM 26±6.9 mM F=0.03, p: ns F=0.03, p: ns
500 μM Peptide (n=8) 3±0.2 mM 7±2.0 mM 16±6.5 mM 25±9.1 mM
Control (n=8) 3±0.2 mM 6±0.9 mM 11±2.0 mM 20±6.2 mM F=0.06, p: ns F=0.04, p: ns
300 μM Peptide (n=5) 3±0.2 mM 6±0.8 mM 11±2.5 mM 21±8.2 mM
Control (n=7) 3±0.3 mM 5±0.6 mM 9±2. 1 mM 17±0.5 mM F=2.87, p: ns F=1.61, p: ns
150 μM Peptide (n=4) 3±0.7 mM 5±1.0 mM 8±2 9 mM 13±6.1 mM
Control (n=13) 3±0.6 mM 5±0.9 mM 10±2.9 mM 18±5.6 mM F=1.01, p: ns F=0.79, p: ns
75 μM Peptide (n=8) 3±0.4 mM 5±1.1 mM 11±2.8 mM 21±5.8 mM
Control (n=12) 3±0.2 mM 5±0.9 mM 10±3.0 mM 18±6.3 mM F=0.21, p: ns F=0.21, p: ns
35 μM Peptide (n=9) 3±0.2 mM 5±1.1 mM 9±2.9 mM 17±7.6 mM
Control (n=8) 3±0.2 mM 5±0.5 mM 8±2.4 mM 15±3.2 mM F=0.14, p: ns F=0.10, p: ns
15 μM Peptide (n=5) 3±0.2 mM 5±0.7 mM 8±3.4 mM 14±4.4 mM
Control (n=13) 3±0.6 mM 9±4.5 mM 17±9.4 mM F=0.19, p: ns F=0.10, p: ns
7.5 μM Peptide (n=15) 3±0.4 mM 9±4.8 mM 16±8.9 mM
Control (n=12) 3±0.6 mM 6±1.7 mM 11±6.2 mM 20±10.8 mM F=0.31, p: ns F=0.28, p: ns
1 μM Peptide (n=13) 3±0.5 mM 6±1.6 mM 12±6.5 mM 22±10.4 mM
Control (n=3) 3±0.2 mM 10±1.1 mM 25±1.0 mM 35±0.8 mM F=0.63, p: ns F=2.24, p: ns
500 nM Peptide (n=4) 3±0.2 mM 9±1.2 mM 24±2.6 mM 34±1.0 mM
Control (n=16) 3±0.5 mM 7±2.6 mM 14±8.7 mM 24±11.8 mM F=0.03, p: ns F=0.002, p: ns
100 nM Peptide (n=19) 3±0.4 mM 7±2.5 mM 14±7.9 mM 24±10.3 mM
Control (n=5) 3±0.1 mM 10±0.8 mM 26±1.0 mM 36±1.2 mM F=6.80, pb0.05 F=9.10, pb0.05
50 nM Peptide (n=5) 3±0.1 mM 8±2.3 mM 19±6.0 mM 29±4.5 mM
Control (n=13) 3±0.6 mM 6±2.3 mM 12±7.5 mM 21±10.9 mM F=0.23, p: ns F=0.04, p: ns
10 nM Peptide (n=14) 3±0.4 mM 6±1.8 mM 10±6.2 mM 21±10.9 mM
Control (n=3) 3±0.5 mM 6±2.6 mM 10±6.5 mM 21±15.3 mM F=0.003, p: ns F=0.005, p: ns
1 nM Peptide (n=5) 3±0.3 mM 6±2.5 mM 10±5.7 mM 20±13.1 mM
For each concentration, the corresponding control values, obtained in the same experimental runs, are reported. Each experiment was repeated at least three times and
the number of data used in each statistical analysis is reported in brackets. No data were available for the 75 μM peptide at 24 h incubation. The statistical analysis was
made using MANOVA.
123D. Basso et al. / Clinica Chimica Acta 372 (2006) 120–128after 4 h incubation; the cells were scraped and lysed using a
50 mmol/L Tris–HCl pH 8.5 buffer containing 1 mmol/L DTT,
1 mmol/L EDTA and 10% protease inhibitor cocktail (Sigma-
Aldrich Inc., USA). After 30 min centrifugation at 4 °C at
14,000 rpm, the supernatants from cells lysates were collected.
Culture media and lysates supernatants were aliquoted and
immediately frozen at −80 °C. Total proteins were measured in
both culture media and lysate supernatants before SDS-PAGE
andWestern blotting. ForWestern blotting, 100 μg proteins were
separated onto a 16.5% discontinuous SDS-PAGE and then
blotted onto a 0.2-μm PVDF membrane (Bio-Rad Laboratories
S.r.l., Milano, Italy). The S100A8 protein was detected using a
specific rabbit polyclonal antibody (kindly supplied by Prof.
Johannes Roth, Münster, Germany) diluted to 1:300.
The statistical analysis of data was made using repeated-
measures analysis of variance (MANOVA), the Fisher's exact
test, the Kruskal–Wallis and the Mann–Whitney tests (SPSS
statistical software).
3. Results
Fig. 1 shows the findings at SDS-PAGE, obtained in
pancreatic cancer tissue samples of patients with or without
diabetes mellitus (Panel A), in pancreatic cancer and adjacentdisease-free pancreatic tissues samples from patients with
pancreatic cancer-associated diabetes (Panel B), in pancreatic
cancer cell lines lysates or a pancreatic tissue sample from a
patient with chronic pancreatitis (Panel C). TheM lines represent
the molecular weight marker and the arrows indicate a peptide
band of about 1500Da, whichwas detected in 7/28 patients, all of
whom had pancreatic cancer; 6/7 of these pancreatic cancer
patients had diabetes mellitus. On evaluating data from the 17
pancreatic cancer patients not taking drugs for diabetes, a
significant association was found between this low-molecular-
weight peptide and the presence of diabetes mellitus (Fisher's
exact test: pb0.05). The 1500-Da peptide was found in cancer
specimens, but not in samples from the adjacent disease-free
pancreatic tissue obtained from the same patients (Fig. 1, panel
B). Furthermore, the 1500-Da peptide was identified in all
pancreatic cancer cell line lysates (Fig. 1, panel C).
Proteins from the tumor sample of one patient with pancreatic
cancer-associated diabetes mellitus were separated by SDS-
PAGE and electro-blotted on a PVDF membrane. The peptide
band of about 1500 Da was cut and directly submitted to amino
acid sequence by automated Edman's degradation; the sequence
obtained was NH2–MLTELEKALNSIID–COOH, which
matched with the N-terminal sequence of the S100A8 protein
(http://kr.expasy.org/).
Table 3
Measurement of caspase-3 activity in myoblasts incubated for 28 h in DMEM
(negative control myoblasts), in DMEM added with 0.01 mmol/L 5-FC (positive
control myoblasts) or 50 nmol/L peptide (tested myoblasts)
Caspase-3 activity
(pmol/min/μg
protein)
Negative
control
myoblasts
Positive control
myoblasts
(0.01 mmol/L 5-FU)
Tested myoblasts
(50 nmol/L
peptide)
Number of repeats 7 3 5
Mean±S.D. 0.198±0.036 0.750±0.115 0.344±0.137
Median 0.203 0.730 ⁎ 0.252 ⁎⁎
Minimum 0.130 0.650 0.240
Maximum 0.250 0.870 0.500
Results, expressed as enzyme activity, represent the mean, the median, and the
standard deviation (S.D.), and the minimum and the maximum values obtained
from 3 to 7 different experimental sets. The statistical analysis (Kruskal–Wallis
test) is also shown.
Kruskal–Wallis test: Chi-square=10.87, pb0.01.
* pb0.05 with respect to negative control and tested myoblasts.
** pb0.05 with respect to negative control myoblasts.
Fig. 3. Morphology of myoblasts after 48 h incubation with control medium
(panel A) or a medium plus 50 nmol/L peptide (panel B).
Fig. 2. Glucose and lactate delta (Δ) from basal concentrations found at 24, 48
and 72 h of incubation in the supernatants of myoblasts incubated with high (0.5,
1 and 2 mmol/L) and low (50, 100 and 500 nmol/L) peptide concentrations.
⁎pb0.01 with respect to control myoblasts; ^pb0.05 with respect to control
myoblasts.
124 D. Basso et al. / Clinica Chimica Acta 372 (2006) 120–128The 1589.88-Da 14 amino acid peptide was then synthesized
and its biological effect on myoblastic glucose metabolism tested
at increasing concentrations.
Tables 1 and 2 show the glucose and lactate levels found in
control myoblasts and in myoblasts incubated with increasing
concentrations of the peptide, together with findings made at
statistical analysis.
Fig. 2 reports glucose and lactate delta (Δ) from basal
concentrations found at 24, 48 and 72 h of incubation in the
supernatants of myoblasts incubated with high (0.5, 1 and
2 mmol/L) and low (50, 100 and 500 nmol/L) peptide
concentrations. The 2 mmol/L peptide caused a significant
decrease in glucose consumption and in lactate accumulation
after 48 h (Mann–WhitneyU=8.0, pb0.05 andU=4.0, pb0.01)
and 72 h (Mann–Whitney U=4.0, pb0.01 and U=4.0, pb0.01)
incubation. The low-concentrations peptide caused a statistically
significant change in the lactate: at a concentration of 50 nmol/L,
it inhibited lactate accumulation after 24 h (Mann–Whitney
U=2.0, pb0.05), 48 h (Mann–WhitneyU=2.0, pb0.05) and 72
h (Mann–Whitney U=0, pb0.01); at 100 nmol/L, it caused a
significant inhibition in lactate production only after 72 h
(Mann–Whitney U=2.0, pb0.01).
Myoblastic growth was stimulated only by the 500 nmol/L
concentrated peptide, whereas none of the other concentrations
affected cell growth (repeated-measures analysis of variance:within-subjects effect: F=4.48, pb0.001; between-subjects
effect: F=6.51, pb0.001).
Fig. 3 shows themorphologyofmyoblasts after 48h incubation
in the control medium or in a medium with added 50 nmol/L
peptide.
Table 3 reports findings for caspase-3 activity measured in
myoblasts incubated in the control medium (negative control) or
in a medium with added 0.01 mmol/L 5-FU (positive control) or
Fig. 4. ESI-mass spectra of active (A) and non-active (B) peptide. Negative ion ESI-mass spectra were obtained from a 10−5 mol/L solution.
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metabolic and morphologic effects on myoblasts if stored as a
powder for more than 1 month at −20 °C instead of −80 °C. We
demonstrated, by ESI-mass spectra analysis, that the loss of
activity was associated with oxidation. In fact, themass spectra ofA
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Fig. 5. (A) SDS-PAGE of cell culture media of monocytes incubated with RPMI
(control monocytes) or CAPAN-1 conditioned media (conditioned monocytes),
stimulated or not stimulated with 1 and 5 μg/mL LPS. M=molecular weight
marker; 1=medium from control non-stimulated monocytes; 2=medium from
conditioned non-stimulated monocytes; 3 and 4=medium from control LPS 1
and 5 μg/mL stimulated monocytes; 5 and 6=medium from conditioned LPS 1
and 5 μg/mL stimulated monocytes; 7=fresh complete medium (RPMI with
10% FCS and 1% glutamine) after overnight monocyte culture; 8=CAPAN-1
conditioned medium. (B) Western blotting results achieved with the anti-
S100A8 polyclonal antibody. 1=CAPAN-1 conditioned monocyte cell lysates;
2=non-conditioned monocytes cell lysates; 3=cell culture medium from
CAPAN-1 conditioned monocytes; 4=cell culture medium from non-condi-
tioned monocytes; 5=LPS (1 μg/mL) stimulated CAPAN-1 conditioned
monocytes cell lysates; 6=LPS stimulated nonconditioned monocytes cell
lysates; 7=cell culture medium from LPS stimulated CAPAN-1 conditioned
monocytes; 8=cell culture medium from LPS stimulated non-conditioned
monocytes; 9=CAPAN-1 conditioned medium.the active peptide (Fig. 4, panel A) revealed a peak of 1587.8 Da,
while that of the inactive peptide (Fig. 4, panel B) revealed two
peaks, one corresponding to the intact molecule and the other,
with a molecular mass of 1603.8 Da, showing the difference in
mass (16 Da) due to an oxygen molecule.
Fig. 5 (panel A) shows findings at SDS-PAGE in cell culture
media of monocytes incubated with RPMI (control monocytes)
or CAPAN-1 conditioned media (conditioned monocytes),
stimulated, or not stimulated, with 1 and 5 μg/mL LPS. Fresh,
nonconditioned medium and CAPAN-1 conditioned medium not
incubated with monocytes were included. The 1500-Da peptide
band was shown in the culture media of LPS stimulated and non-
stimulated control monocytes and in the CAPAN-1 conditioned
medium, but it was no longer detected in the supernatants of
CAPAN-1 conditioned monocytes stimulated, or not stimulated,
with LPS. Similar results were obtained following SDS-PAGE of
monocyte cell lysates. In Fig. 5 (panel B), the results of Western
blotting achieved with the anti-S100A8 polyclonal antibody are
also shown. This antibody reacted against a protein band of about
6000 Da, corresponding to the entire S100A8 protein, but it did
not recognize the 1500-Da peptide, corresponding to the N-
terminal sequence of the same protein.
4. Discussion
Glucose metabolic alterations in cultured hepatocytes and
myoblasts conditioned by pancreatic cancer cell lines can be
reproduced by low-molecular-weight (b10,000 Da) fractions of
the same conditionedmedia [10,13]. Furthermore, findings made
at MALDI-TOF (matrix-assisted laser desorption ionization–
time of flight) analysis of patients' sera and pancreatic cancer cell
conditioned media suggest that a low-molecular-weight peptide
is correlated with pancreatic cancer-associated diabetes [16]. To
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the separation of peptides with a molecular weight of less than
10,000 Da. Pancreatic cancer tissue samples, from patients with
or without diabetes mellitus, were analyzed by SDS-PAGE. A
peptide band of about 1500Da, detected in samples from patients
with diabetes, was not found in the non-neoplastic pancreas
adjacent to the tumors of the same diabetic patients: this result,
although obtained from a limited series of patients, too small to
draw any definitive conclusion, suggests, however, that the
peptide is a tumor-derived product associated with diabetes. This
is further borne out by the analysis of (1) a series of pancreatic
cancer cell lines, which all presented the peptide following
electrophoresis, and (2) pancreatic tissue samples from patients
without pancreatic cancer, in none of which was the peptide
observed. As these findings were consistent with the hypothesis
that the SDS-PAGE-evidenced 1500-Da peptide might be the
putative pancreatic cancer-associated diabetogenic factor, se-
quence analysis was performed on the corresponding SDS-PAGE
band using Edman degradation. The resulting amino acid
sequence corresponded to a 14 amino acid peptide with a
molecular mass of 1589.88 Da, which matched the N-terminal
sequence of the S100A8 protein. This protein (also known as
Calgranulin A, migration inhibitory factor-related protein (MRP-
8), cystic fibrosis antigen (CFAG), calprotectin L1L subunit,
urinary stone protein band A, and leukocyte L1 complex light
chain), belongs to the family of the S100 calcium binding
proteins [20–23]. The major S100 gene cluster, located on
chromosome 1q21.3, comprises at least 17 members numbered
from S100A1 to S100A17, while the S100B locus is located
outside this cluster on chromosome 21q22.3 [23]. Most S100
proteins have a mass of about 9–14 kDa with a conserved C-
terminal characterized by a common structuralmotif, the EF hand
having a high affinity for calcium. The N-terminal of these
proteins contains a non-canonical EF hand, with two additional
amino acids (14 instead of 12) which, in some S100s, binds Ca2+
with low affinity [20–23]. This family of proteins plays several
biological roles, regulating enzyme activity, cytoskeleton organi-
zation dynamics, cell growth and differentiation, and Ca2+homeo
stasis. Although S100 proteins are structurally related, differ-
ences in their expression profiles and subtle differences in their
activity may underlie non-redundant functions. S100A8, in par-
ticular, plays a fundamental role in embryogenesis and inflam-
mation [22,24–27]. In cancer cells, S100 proteins seem to have a
positive overall effect on cell survival, by modifying the
expression of pro-survival genes [28]; altered S100s expression
has been found in several types of solid tumor [29–33]. Over-
expression of S100s has also been observed in pancreatic cancer
[34–38], and S100A8 protein levels were recently found to be
significantly increased in tumors compared with normal and
pancreatitis tissues [39]. To verify whether the N-terminal
peptide of the S100A8 protein has a diabetogenic effect, we
tested increasing concentrations of the newly synthesized
molecule in cultured myoblasts, known to have a glucose
metabolism sensitive to the effects of pancreatic cancer
conditioned media [13,40]. Glucose and lactate levels were
measured in the supernatants ofmyoblasts incubated for 24, 48 or
72 h in control medium or in amedium containing different (fromnanomolar to millimolar) amounts of the peptide. Both at high
(2 mmol/L) and low (50 nmol/L) concentrations, the peptide
caused a reduction in glucose utilization and in lactate production
over time, suggesting that it interferes with the glucose
metabolism of myoblasts. These effects of low and high
concentrations on myoblasts glucose metabolism were, at least
in part, dose related. The inhibition of glucose utilization at a
2 mmol/L concentration after 48 and 72 h of incubation
progressively declined when myoblasts were treated with 1 or
0.5 mmol/L. Accordingly, maximal inhibition of lactate
production was recorded after 72 h incubation with 2 mmol/L
peptide, the effects of 1 and 0.5 mmol/L peptide being
intermediate. Likewise, low peptide concentrations inhibited
lactate production in a dose-dependent fashion, the effects being
evident after 24 h.
The above findings confirm that the pancreatic cancer-derived
peptide can alter glucose metabolism, although in restricted and
varying ranges of concentration. The biological effects of
different concentrations of the peptide have been reported on
by other authors for other S100 proteins, particularly for S100B,
which, at nanomolar amounts, enhances neuronal survival and
stimulates neurite outgrowth and astrocytic proliferation and at
micromolar concentrations causes neuronal and astrocytic
apoptosis and stimulates IL-6 secretion through the release of
nitric oxide by astrocytes and microglia [21,41].
Like S100B, the S100A8 N-terminal peptide had opposite
effects on myoblastic growth at different concentrations. At
500 nmol/L, it enhanced growth, whereas at 2 mmol/L and
50 nmol/L, it caused alterations in the myoblastic morphology:
the cells appeared rounded, accumulated at the edge of culture
wells and were less differentiated, and some were polynucleated.
Thesemorphological alterations were paralleled by an increase in
caspase-3 activity, suggesting that the N-terminal peptide of the
S100A8 protein triggers the apoptotic cascade. The morpholog-
ical alterations found by us in treated myoblasts have already
been described after exposure to S100B, which causes apoptosis
by inhibiting extracellular signal-regulated kinase (ERK) 1/2
[42,43]. The effects of the peptide on myoblastic glycolysis and
morphology probably occur independent of calcium binding,
since the 14 amino acid peptide studied by us does not contain the
EF hand, probably depending on its interaction with cytoskeletal
proteins like actin, known to be a target for the interaction of
various S100s [21,24,41].
The results obtained in the present study provide further
evidence that a small part of a molecule may have significant
biological effects, as already demonstrated for S100C/A11 frag-
ments [44]. The effects of the S100A8 N-terminal peptide on
glucose metabolism and cell growth were observed when the
intact peptide was used, but not when the latter was oxidized, a
phenomenon found when the molecule was stored at −20 °C
rather than at −80 °C, as demonstrated by ESI-mass spectra
analysis. This finding, which demonstrates the specificity of the
biological action of the N-terminal of S100A8, is in agreement
with previous results obtainedwith the entiremolecule,which fails
to exert a chemotactic activity if oxidized by hypochlorite [45].
Although the findings made by us on pancreatic cancer cell
lines support the hypothesis that the N-terminal peptide of
127D. Basso et al. / Clinica Chimica Acta 372 (2006) 120–128S100A8 is produced by tumor cells, we cannot rule out that it
derives from inflammatory cells that normally produce the
S100A8 protein, monocytes and polymorphonuclear cells, in
particular [22]. As demonstrated by Western blot analysis,
isolated monocytes release the entire S100A8 in the culture
medium. These inflammatory cells were found to release also the
N-terminal fragment of this protein. However, when monocytes
were conditioned by pancreatic cancer derivedmedia, this peptide
was no longer detected. Overall, our results indicate that the N-
terminal peptide of the S100A8 protein is produced and released
by pancreatic cancer cells and monocytes, and that it is probably
not a degradation product from inflammatory cells. Its disappear-
ance in monocyte media after pancreatic cancer cell conditioning
may occur consequent to a feed-back regulation, as already
described for the entire S100A8 and S100A9 proteins [22].
In conclusion, the findings made in the present study indicate
that the 14 amino acid N-terminal peptide of the S100A8,
produced by pancreatic tumor cells and monocytes, impairs glu-
cose metabolism, an alteration frequently encountered in pan-
creatic cancer.
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